<DOC>
	<DOCNO>NCT01642914</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety linaclotide compare placebo patient chronic constipation ( CC ) prominent abdominal bloating . This study include 3-week screening period 2-3 week pretreatment period . Patients eligible randomized one two dos linaclotide placebo 12 week . This 12-week study ass effect linaclotide bowel movement frequency , well abdominal bowel symptom CC .</brief_summary>
	<brief_title>Safety Efficacy Linaclotide Patients With Chronic Constipation Prominent Abdominal Bloating</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Patient complete colonoscopy accord American Gastroenterological Association criterion clinically significant finding Patient successfully complete protocol procedure ( clinically significant finding ) Patient meet protocol criterion Chronic Constipation ( CC ) : &lt; 3 bowel movement per week report one follow symptom least 12 week : 1 . Straining 25 % BMs 2 . Lumpy hard stool 25 % BMs 3 . Sensation incomplete evacuation 25 % BMs Patient demonstrate continue chronic constipation bloat Pretreatment Period Patient compliant Interactive voice response System ( IVRS ) Patient history loose watery stool Patient symptom diagnose Irritable Bowel Syndrome ( IBS ) Patient structural abnormality gastrointestinal ( GI ) tract disease condition affect GI motility Patient protocolexcluded clinically significant medical surgical history would limit patient 's ability complete participate clinical trial could confound study assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Chronic Constipation</keyword>
	<keyword>Abdominal Bloating</keyword>
	<keyword>Linaclotide</keyword>
</DOC>